# A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

> **NCT07644286** · PHASE2 · RECRUITING · sponsor: **Tao Zhang** · enrollment: 48 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Pirfenidone in combination with a PD-1 inhibitor
- **RADIATION:** hypofractionated radiotherapy

## Key facts

- **NCT ID:** NCT07644286
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-01-25
- **Final completion:** 2027-12-25
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644286, "A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*